No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy
- 14 June 2020
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (9), E433-E434
- https://doi.org/10.1111/jdv.16552
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 2020
- Papa Giovanni XXIII Bergamo Hospital at the time of the COVID-19 outbreak: Letter from the warfront ...International Journal of Laboratory Hematology, 2020
- Critical Care Utilization for the COVID-19 Outbreak in Lombardy, ItalyJAMA, 2020
- Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexityJournal of Dermatological Treatment, 2020
- Art of performing dermoscopy during the times of coronavirus disease (COVID‐19): simple change in approach can save the day!Journal of the European Academy of Dermatology and Venereology, 2020
- Cutaneous manifestations in COVID‐19: a first perspectiveJournal of the European Academy of Dermatology and Venereology, 2020
- Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled AnalysisAmerican Journal of Clinical Dermatology, 2019
- Dupilumab: A review of its use in the treatment of atopic dermatitisJournal of the American Academy of Dermatology, 2018